Published in J Infect Dis on July 17, 2012
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22
Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol (2014) 1.11
Treatment Options in Hepatitis C. Dtsch Arztebl Int (2017) 1.10
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol (2014) 1.08
Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98
Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV. J Acquir Immune Defic Syndr (2014) 0.96
Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis (2016) 0.96
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther (2013) 0.92
Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol (2016) 0.91
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol (2016) 0.90
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine (2014) 0.89
Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne) (2015) 0.89
Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol (2014) 0.86
Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction (2013) 0.86
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr (2015) 0.85
Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. Int J Endocrinol (2014) 0.84
Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One (2014) 0.83
Socioeconomic status in HCV infected patients - risk and prognosis. Clin Epidemiol (2013) 0.83
Chronic hepatitis C infection as a risk factor for renal cell carcinoma. Dig Dis Sci (2015) 0.83
Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int (2013) 0.82
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV. Dig Dis Sci (2016) 0.81
The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study. Medicine (Baltimore) (2016) 0.81
Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review. World J Gastroenterol (2015) 0.80
Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol (2015) 0.80
Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline. Can J Gastroenterol Hepatol (2014) 0.80
Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr (2014) 0.80
Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther (2015) 0.79
New insights into HCV-related rheumatologic disorders: A review. J Adv Res (2016) 0.79
Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities. J Infect Public Health (2014) 0.79
Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study. BMJ Open (2015) 0.79
The impact of chronic hepatitis C virus infection on mortality. J Infect Dis (2012) 0.79
Impact of hepatitis coinfection on healthcare utilization among persons living with HIV. J Acquir Immune Defic Syndr (2015) 0.78
Environmental Issues in Thyroid Diseases. Front Endocrinol (Lausanne) (2017) 0.78
Association Between Hepatitis C Virus and Head and Neck Cancers. J Natl Cancer Inst (2016) 0.78
Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study. World J Gastroenterol (2014) 0.78
Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus. Hepat Res Treat (2016) 0.78
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int (2016) 0.77
Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol (2014) 0.77
Mediation effect of hepatitis B and C on mortality. Eur J Epidemiol (2016) 0.77
The New Era of Interferon-Free Treatment of Chronic Hepatitis C. Viszeralmedizin (2015) 0.77
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol (2016) 0.77
Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep (2015) 0.77
Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol (2016) 0.76
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res (2016) 0.76
Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther (2016) 0.76
Antiviral drug allergy. Immunol Allergy Clin North Am (2014) 0.76
Bystander hyperactivation of preimmune CD8(+) T cells in chronic HCV patients. Elife (2015) 0.76
Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder. PLoS One (2017) 0.75
Predictors for Early Identification of Hepatitis C Virus Infection. Biomed Res Int (2015) 0.75
Hepatitis C virus and cardiovascular: A review. J Adv Res (2016) 0.75
Systemic manifestations of hepatitis C infection. Infect Agent Cancer (2016) 0.75
Management of HCV-Associated Liver Cirrhosis. Visc Med (2016) 0.75
Increased mortality in chronic HCV infection. Ann Hepatol (2012) 0.75
Follow-up testing for hepatitis C virus infection: an analysis of Massachusetts surveillance data, 2007-2010. Public Health Rep (2014) 0.75
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus. Oncotarget (2016) 0.75
Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer (2016) 0.75
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy. Eur J Clin Microbiol Infect Dis (2016) 0.75
Outlier populations: individual and social network correlates of solvent-using injection drug users. PLoS One (2014) 0.75
Impact of hepatitis C status on 20-year mortality of patients with substance use disorders. Addict Sci Clin Pract (2015) 0.75
Grazoprevir/elbasvir combination therapy for HCV infection. Therap Adv Gastroenterol (2016) 0.75
Extrahepatic manifestations in hepatitis C virus infection. J Adv Res (2016) 0.75
Anti-hepatitis C virus drugs and kidney. World J Hepatol (2016) 0.75
Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis (2017) 0.75
HCV treatment in children and young adults with HIV/HCV co-infection in Europe. J Virus Erad (2015) 0.75
Chronic hepatitis infection is associated with extrahepatic cancer development: a nationwide population-based study in Taiwan. BMC Cancer (2016) 0.75
Glucose abnormalities in Asian patients with chronic hepatitis C. Drug Des Devel Ther (2015) 0.75
Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy. J Clin Exp Hepatol (2016) 0.75
HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care. Am J Prev Med (2015) 0.75
Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat (2017) 0.75
The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin (2017) 0.75
Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. J Gastroenterol (2015) 0.75
FIB-4 stage of liver fibrosis predicts incident heart failure among HIV infected and uninfected patients. Hepatology (2017) 0.75
Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. Curr Epidemiol Rep (2017) 0.75
Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals. J Clin Transl Hepatol (2017) 0.75
Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J Clin Transl Hepatol (2017) 0.75
Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med (2017) 0.75
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med (2007) 10.47
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A (2008) 4.06
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis (2003) 2.47
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Clinical characteristics and prognostic factors of splenic abscess: a review of 67 cases in a single medical center of Taiwan. World J Gastroenterol (2006) 2.41
Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA (2004) 2.39
Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology (2012) 2.35
Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol (2010) 2.32
The effects of chronic arsenic exposure from drinking water on the neurobehavioral development in adolescence. Neurotoxicology (2003) 2.29
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology (2007) 2.20
C-reactive protein concentration as a significant correlate for metabolic syndrome: a Chinese population-based study. Endocrine (2012) 2.19
Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst (2011) 2.18
Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med (2010) 2.17
Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol (2003) 2.09
Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol (2013) 2.06
Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res (2007) 2.02
The effect of in-hospital developmental care on neonatal morbidity, growth and development of preterm Taiwanese infants: a randomized controlled trial. Early Hum Dev (2012) 1.98
High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer (2004) 1.95
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology (2009) 1.95
Testing the 8-syndrome structure of the child behavior checklist in 30 societies. J Clin Child Adolesc Psychol (2007) 1.94
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology (2010) 1.89
A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. J Natl Cancer Inst (2006) 1.88
Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol (2002) 1.88
Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol (2010) 1.88
Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. Am J Epidemiol (2015) 1.87
Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke (2010) 1.82
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology (2012) 1.81
Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst (2002) 1.79
Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation (2002) 1.78
Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology (2010) 1.78
Cancer trends in Taiwan. Jpn J Clin Oncol (2010) 1.73
Regression-based association analysis with clustered haplotypes through use of genotypes. Am J Hum Genet (2005) 1.71
The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer (2008) 1.71
Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology (2007) 1.70
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology (2010) 1.69
Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 1.66
Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int (2009) 1.65
Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol (2005) 1.64
Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol (2003) 1.63